期刊文献+

阈下微脉冲激光与氩离子激光治疗糖尿病性黄斑水肿的临床随机对照研究(英文) 被引量:8

Randomized, controlled clinical trial comparison of SDM laser versus argon ion laser in diabetic macular edema
在线阅读 下载PDF
导出
摘要 目的:比较阈下微脉冲激光(波长810nm)同氩离子激光(波长514nm)治疗糖尿病性黄斑水肿的疗效。方法:采用临床随机对照研究的方法对84例99眼进行分组,并分别行810nm激光与514nm激光,治疗后随访6mo,行最佳矫正视力、FFA、OCT检查,评估疗效。结果:50眼及49眼分别完成了810nm激光及514nm激光治疗,治疗后随访结果显示:无论810nm还是514nm激光均能稳定及提高视力,二组间差异无统计学意义(P>0.05);治疗前后视网膜厚度及黄斑水肿均有所改善,且自身治疗前后差异有统计学意义(P<0.05),二组间差异无统计学意义(P>0.05)。结论:无论810nm激光还是514nm激光均可以一定程度的稳定及提高视力,且对糖尿病性黄斑水肿治疗有效,二者间的差异无统计学意义。 AIM: To compare the efficacy of subthreshold micropulse diode ( SDM) laser treatment and argon ion la ser treatment for diabetic macular edema ( DME) . METHODS: A prospective, randomized controlled trial was carried out in 84 patients (99 eyes), in which, 49 eyes received argon ion laser treatment and 50e yes received SDM laser treatm ent. The changes in best corrected visual acuity ( BCVA ) , baseline fluorescein angiography and optic coherence tomography measurements were evaluated in both groups.Follow-up visit was over 6 months from baseline. RESULTS:Ninety-nine eyes (84 patients ) complete the study.Six months after treatment, the BCVA improved 22.4%a nd 02 .0%eyesi n argon io n laser group and SDM laser group respectivel y.55.1% and 5 8.0% eyesr eceived ste ady BCVA.Edem a par tial regression was accounted for 49% in argon ion laser group, while th at was 56% in SDM laser group. No statistically signi fica nt changes were found in ea chgr oup. CONCLUSION:No matter argon ion laser or SDM laser is effective to keep or improve the VA in DME.After 6-month follow -up , there is no statistically significant dif ference between them.
出处 《国际眼科杂志》 CAS 2013年第12期2370-2372,共3页 International Eye Science
基金 乌鲁木齐科技局基金(No.T101310005)~~
关键词 阁下微脉冲激光 氩离子激光 糖尿病性黄斑水肿 argon ion laser SDM laser diabeticmacular edema
  • 相关文献

参考文献9

  • 1Lain DS, Ritch R, Rao SK. Laser and Pharmacologic Therapies for Macular Diseases. Section B the sixth ed.
  • 2Li SZ. Ophthalmic surgery. Beijing: People's Health Publishing House, 2002:726, 951.
  • 3Finger PT, Packer S, Paglione RW. Thermoradiotherapy of choroidal melanoma. Ophthalmology 1989 ,96:1384-1388.
  • 4EarlyTreatment Diabetic Retinopathy Study Group. Photocoagulation for diabetic macular edema. Int Ophthalmol Clinic 1987 ,27:265-272.
  • 5Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994 , 112:480-488.
  • 6Moorman CM, Hamihon AM. Clinical applications of the mieropulse diode laser. Eye 1999 ,13:145-150.
  • 7Laursen ML, Moeller F, Sander B, Sjoelie AK. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 2004 , 88 : 1173-1179.
  • 8Akduman L, Olk ILl. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic maeular edema (DDME). Ophthalmic Surg Lasers 1999 ,30:705.
  • 9Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 2005 ,89:74-80.

同被引文献51

  • 1陈得谜,任韩,李豪,郭翠玲.康柏西普与雷珠单抗联合577nm微脉冲激光在糖尿病黄斑水肿治疗中的疗效差异[J].现代医学,2021,49(8):959-964. 被引量:3
  • 2Pedro Romero-Aroca.Managing diabetic macular edema: The leading cause of diabetes blindness[J].World Journal of Diabetes,2011,2(6):98-104. 被引量:16
  • 3Ciardella AP, Klancnik J, Schiff W, et al. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 2004;88(9) :1131-1136.
  • 4Li X, Xu G, Wang Y, et al . Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study : AURORA study. Ophthalmology 2014 ; 121 (9) :1740-1747.
  • 5Chun MY, Hwang HS, Cho HY, et al . Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J Clin Endocrinol Metab 2010 ;95 (7) : 3547-3551.
  • 6Funastu H, Yanashita H, Lkeda T, et al. Angiotensin- 11 and vascular endothelial. Am J Ophthalmol 2002 ; 133 ( 2 ) :537-543.
  • 7Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006 ;90(12) :1542-1547.
  • 8Crawford TN, Alfaro DV 3rd, Kerrison JB, et al. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009 ;5( 1 ) :8-13.
  • 9Burak T, Tanyildizi R. The frequency of the nonresponsiveness to intravitreal injection of the anti-vascular endothelial growth factor agent in neovascular age related macular degeneration. Int J Ophthalmic Pathol 2013 ;2(3 ) :2324-2326.
  • 10Ciardella AP, Klancnik J, Schiff W, et al. Intravitreal tfiamcinolone for the treatment of refractory diabetic maeular oedema with hard exudates: an optical coherence tomography study [ J ]. Br J Ophthalmo1,2004,88 (9) : 1131-1136.

引证文献8

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部